Bio-Techne (TECH) Declares $0.32 Quarterly Dividend; 0.5% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bio-Techne (TECH) Tops Q4 EPS by 25c
August 4, 2020 6:31 AM EDTBio-Techne (NASDAQ: TECH) reported Q4 EPS of $1.00, $0.25 better than the analyst estimate of $0.75. Revenue for the quarter came in at $175.8 million versus the consensus estimate of $163.91 million.
For earnings history and earnings-related data on Bio-Techne (TECH) click here.
... MoreBio-Techne (TECH) Adds Julie L. Bushman to Board
August 3, 2020 7:09 AM EDTBio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Julie L. Bushman to serve as an independent director on the company's board of directors, effective as of July 31, 2020. Following the appointment, the board of Bio-Techne will be comprised of ten directors, nine of... More
Bio-Techne (TECH) And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test
August 3, 2020 7:07 AM EDTBio-Techne Corporation (NASDAQ: TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available for research use in early August.
The COVID-SeroIndex test kit is an enzyme-linked immunosorbent assay, or ELISA, designed to measure the presence or... More
